chylomicronemia syndrome

FDA approves drug to reduce triglycerides in adult patients with familial chylomicronemia syndrome

by

Action 🔹The U.S. Food and Drug Administration has approved Tryngolza (olezarsen), used with diet, to reduce triglycerides (TG) in adults with familial chylomicronemia syndrome (FCS). This is a first-in-class approval, meaning Tryngolza uses a new mechanism of action, or works differently in the body, than other therapies currently used to treat FCS. 🔹Tryngolza is injected subcutaneously … Read more